KBC Group NV Acquires 250,458 Shares of IQVIA Holdings Inc. (NYSE:IQV)

KBC Group NV grew its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 68.5% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 616,299 shares of the medical research company’s stock after buying an additional 250,458 shares during the period. KBC Group NV’s holdings in IQVIA were worth $121,109,000 as of its most recent filing with the SEC.

Other large investors also recently modified their holdings of the company. Capital Performance Advisors LLP bought a new position in IQVIA during the third quarter worth $27,000. Park Place Capital Corp bought a new position in shares of IQVIA during the 3rd quarter worth about $28,000. Avior Wealth Management LLC grew its stake in shares of IQVIA by 117.6% in the 3rd quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company’s stock valued at $38,000 after buying an additional 87 shares during the period. Assetmark Inc. increased its position in IQVIA by 612.5% in the 3rd quarter. Assetmark Inc. now owns 228 shares of the medical research company’s stock valued at $54,000 after buying an additional 196 shares in the last quarter. Finally, UMB Bank n.a. boosted its holdings in IQVIA by 74.4% in the third quarter. UMB Bank n.a. now owns 232 shares of the medical research company’s stock worth $55,000 after acquiring an additional 99 shares in the last quarter. Institutional investors and hedge funds own 89.62% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on IQV. Barclays reduced their price target on shares of IQVIA from $260.00 to $255.00 and set an “overweight” rating for the company in a research report on Friday, November 1st. Morgan Stanley decreased their price target on IQVIA from $280.00 to $265.00 and set an “overweight” rating for the company in a report on Monday, November 4th. Leerink Partners reaffirmed an “outperform” rating and set a $248.00 price objective (down from $260.00) on shares of IQVIA in a report on Tuesday, November 19th. Truist Financial dropped their price target on shares of IQVIA from $265.00 to $261.00 and set a “buy” rating on the stock in a research report on Thursday, December 12th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and issued a $270.00 price objective on shares of IQVIA in a research report on Wednesday, December 11th. Four analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $255.71.

IQVIA Stock Down 0.7 %

IQV opened at $204.54 on Monday. The company has a 50 day moving average of $199.71 and a 200 day moving average of $221.11. The company has a current ratio of 0.81, a quick ratio of 0.81 and a debt-to-equity ratio of 1.76. IQVIA Holdings Inc. has a 12 month low of $187.62 and a 12 month high of $261.73. The company has a market cap of $37.12 billion, a PE ratio of 26.84, a price-to-earnings-growth ratio of 2.14 and a beta of 1.48.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.